



# Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study

Ami D. Sperber,<sup>1</sup> Shrikant I. Bangdiwala,<sup>2,3</sup> Douglas A. Drossman,<sup>4</sup> Uday C. Ghoshal,<sup>5</sup> Magnus Simren,<sup>6</sup> Jan Tack,<sup>7</sup> William E. Whitehead,<sup>8</sup> Dan L. Dumitrascu,<sup>9</sup> Xuicai Fang,<sup>10</sup> Shin Fukudo,<sup>11</sup> John Kellow,<sup>12</sup> Edith Okeke,<sup>13</sup> Eamonn M. M. Quigley,<sup>14</sup> Max Schmulson,<sup>15</sup> Peter Whorwell,<sup>16</sup> Timothy Archampong,<sup>17</sup> Payman Adibi,<sup>18</sup> Viola Andresen,<sup>19</sup> Marc A. Benninga,<sup>20</sup> Bruno Bonaz,<sup>21</sup> Serhat Bor,<sup>22</sup> Luis Bustos Fernandez,<sup>23</sup> Suck Chei Choi,<sup>24</sup> Enrico S. Corazzari,<sup>25</sup> Carlos Francisconi,<sup>26</sup> Albis Hani,<sup>27</sup> Leonid Lazebnik,<sup>28</sup> Yeong Yeh Lee,<sup>29</sup> Agata Mulak,<sup>30</sup> M. Masudur Rahman,<sup>31</sup> Javier Santos,<sup>32</sup> Mashiko Setshedi,<sup>33</sup> Ari Fahrial Syam,<sup>34</sup> Stephen Vanner,<sup>35</sup> Reuben K. Wong,<sup>36</sup> Aurelio Lopez-Colombo,<sup>37</sup> Valeria Costa,<sup>27</sup> Ram Dickman,<sup>38</sup> Motoyori Kanazawa,<sup>11</sup> Ammar Hassanzadeh Keshteli,<sup>39</sup> Rutaba Khatun,<sup>3</sup> Iradj Maleki,<sup>40</sup> Pierre Poitras,<sup>41</sup> Nitesh Pratap,<sup>42</sup> Oksana Stefanyuk,<sup>43</sup> Sandie Thomson,<sup>33</sup> Judith Zeevenhooven,<sup>20</sup> and Olafur S. Palsson<sup>8</sup>


<sup>1</sup>Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; <sup>2</sup>Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Ontario, Canada; <sup>3</sup>Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada; <sup>4</sup>Center for Functional GI & Motility Disorders, University of North Carolina, Center for Education and Practice of Biopsychosocial Care, and Drossman Gastroenterology, Chapel Hill, North Carolina; <sup>5</sup>Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGI), Lucknow, India; <sup>6</sup>Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; <sup>7</sup>Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium; <sup>8</sup>Center for Functional GI & Motility Disorders, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina; <sup>9</sup>Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania; <sup>10</sup>Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>11</sup>Department of Behavioral Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan; <sup>12</sup>Discipline of Medicine, Northern Clinical School, University of Sydney, Sydney, Australia; <sup>13</sup>Department of Medicine, University of Jos, Jos University Teaching Hospital, Jos, Nigeria; <sup>14</sup>Lynda K. and David M. Underwood Center for Digestive Disorder, Gastroenterology and Hepatology, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas; <sup>15</sup>Laboratory of Liver, Pancreas and Motility (HIPAM), Unit of Research in Experimental Medicine, Faculty of Medicine, Universidad Nacional Autónoma de México (UNAM), Hospital General de México, Mexico City, Mexico; <sup>16</sup>Neurogastroenterology Unit, Manchester University NHS Foundation Trust, Wythenshawe Hospital, Manchester, United Kingdom; <sup>17</sup>Department of Medicine, University of Ghana School of Medicine and Dentistry, Accra, Ghana; <sup>18</sup>Integrative Functional Gastroenterology Research Center, Department of Internal Medicine, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran; <sup>19</sup>Department of Medicine, Israelitic Hospital, Hamburg, Germany; <sup>20</sup>Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Pediatric Gastroenterology, Amsterdam, The Netherlands; <sup>21</sup>Service d'Hépatogastroentérologie, CHU Grenoble Alpes, Grenoble, France; <sup>22</sup>Ege University School of Medicine, Division of Gastroenterology, Bornova Izmir, Turkey; <sup>23</sup>"Centro Medico Dr. Bustos Fernandez", Buenos Aires, Argentina; <sup>24</sup>Department of Gastroenterology, School of Medicine, Wonkwang University, Iksan, Korea; <sup>25</sup>Department of Gastroenterology, Istituto Clinico Humanitas, Rozzano, Italy; <sup>26</sup>Department of Internal Medicine, Universidade Federal do Rio Grande do Sul, Gastroenterology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil; <sup>27</sup>Gastroenterology Unit, Hospital Universitario San Ignacio, Pontificia Universidad Javeriana, Bogotá, Colombia; <sup>28</sup>Department of Outpatient Medicine, Faculty of Internal Medicine, Moscow State University of Medicine and Dentistry, Moscow, Russia; <sup>29</sup>School of Medical Sciences, Universiti Sains Malaysia, Kota Bharu, Kelantan, Malaysia; <sup>30</sup>Department of Gastroenterology and Hepatology, Wroclaw Medical University, Wroclaw, Poland; <sup>31</sup>Dhaka Medical College & Hospital, Dhaka, Bangladesh; <sup>32</sup>Department of Gastroenterology, University Hospital Vall d'Hebron, Autonomous University of Barcelona & Neuro-Immuno-Gastroenterology Lab, Vall d'Hebron Research Institute, Barcelona, Spain; <sup>33</sup>Department of Medicine, Division of Gastroenterology, University of Cape Town, Cape Town, South Africa; <sup>34</sup>Division of Gastroenterology, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Cipto Mangunkusumo Hospital, Jakarta, Indonesia; <sup>35</sup>Gastrointestinal Diseases Research Unit, Kingston Health Science Centre, Queen's University, Kingston, Ontario, Canada; <sup>36</sup>Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore; <sup>37</sup>UMAE Hospital de Especialidades C.M.N. Manuel Avila Camacho, Puebla Pue, Mexico; <sup>38</sup>Division of Gastroenterology, Rabin Medical Center, Sackler School of Medicine, Tel-Aviv, Israel; <sup>39</sup>CEGIIR-Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada; <sup>40</sup>Gut and Liver Research Center, Department of Internal Medicine, Mazandaran University of Medical Sciences, Sari, Iran; <sup>41</sup>CHUM, Université de Montréal, Montréal, Quebec, Canada; <sup>42</sup>KIMS Hospitals, Secunderabad, India; and <sup>43</sup>Department of Biochemical Markers of Chronic Non-Communicable Diseases Research National Medical Research Centre for Preventive Medicine, Moscow, Russia

A global epidemiological study of functional GI disorders

- 73,076 adults surveyed (33 countries, 6 continents)
- Data collection: By Internet (24 countries, blue), by household interview (7 countries, yellow), or both methods (China and Turkey, green).

Prevalence of meeting criteria for at least one of 22 functional GI disorders (%):

	All Participants	Females	Males
Internet surveys	40.3	46.5	34.2
Household surveys	20.7	23.1	18.3



Gastroenterology

**BACKGROUND & AIMS:** Although functional gastrointestinal disorders (FGIDs), now called disorders of gut-brain interaction, have major economic effects on health care systems and adversely affect quality of life, little is known about their global prevalence and distribution. We investigated the prevalence of and factors associated with 22 FGIDs, in 33 countries on 6 continents. **METHODS:** Data were collected via the Internet in 24 countries, personal interviews in 7 countries, and both in 2 countries, using the Rome IV diagnostic questionnaire, Rome III irritable bowel syndrome questions, and 80 items to identify variables associated with FGIDs. Data collection methods differed for Internet and household groups, so data analyses were conducted and reported separately. **RESULTS:** Among the 73,076 adult respondents (49.5% women), diagnostic criteria were met for at least 1 FGID by 40.3% persons who completed the Internet surveys (95% confidence interval [CI], 39.9–40.7) and 20.7% of persons who completed the household surveys (95% CI, 20.2–21.3). FGIDs were more prevalent among women than men, based on responses to the Internet survey (odds ratio, 1.7; 95% CI, 1.6–1.7) and household survey (odds ratio, 1.3; 95% CI, 1.3–1.4). FGIDs were associated with lower quality of life and more frequent doctor visits. Proportions of subjects with irritable bowel syndrome were lower when the Rome IV criteria were used, compared with the Rome III criteria, in the Internet survey (4.1% vs 10.1%) and household survey (1.5% vs 3.5%). **CONCLUSIONS:** In a large-scale multinational study, we found that more than 40% of persons worldwide have FGIDs, which affect quality of life and health care use. Although the absolute prevalence was higher among Internet respondents, similar trends and relative distributions were found in people who completed Internet vs personal interviews.

**Keywords:** DGBI; IBS; epidemiology.

mucosal and immune function, altered gut microbiota, and altered central nervous system processing.<sup>1</sup> They result in significant global health care costs<sup>2–4</sup> and impaired health-related quality of life (QOL).<sup>5</sup> However, population-based cross-sectional surveys have not satisfactorily delineated their actual prevalence. Published studies have involved highly variable diagnostic criteria, study populations, questionnaires, and data collection methods.<sup>6–8</sup> For irritable bowel syndrome (IBS) and functional dyspepsia (FD), the 2 most researched disorders, reported prevalence estimates are very broad (1.1%–45.0% for IBS,<sup>9</sup> and 1.8%–57.0% for FD).<sup>10,11</sup> Thus, given the large methodological heterogeneity, it is inappropriate to pool individual prevalence rates, and we are left with an unanswered question as to whether the differences in prevalence rates seen among individual countries in prior surveys reflect genuine differences between populations or are due to methodological differences between studies.

The ideal global epidemiological study would use uniform methodology to assess nationally representative populations of sufficient size throughout the world, but this is not feasible. The present study, conducted in 33 countries at the same time, did use standardized methodology (although circumstances mandated 2 different data collection methods), with identical diagnostic questions to approximate to that ideal, assessed the global prevalence and burden of FGIDs, including sub-analyses by country, sex, and age groups. The results are summarized for all FGIDs, but the main focus is on 5 prevalent disorders because they

**Abbreviations used in this paper:** CI, confidence interval; EPS, epigastric pain syndrome; FC, functional constipation; FD, functional dyspepsia; FGID, functional gastrointestinal disorder; GI, gastrointestinal; IBS, irritable bowel syndrome; IBS-SSS, IBS symptom severity scale; OR, odds ratio; PDS, postprandial distress syndrome; PROMIS, Patient-Reported Outcomes Measurement Information System; QOL, quality of life.

Most current article

© 2021 by the AGA Institute. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

0016-5085

<https://doi.org/10.1053/j.gastro.2020.04.014>

The functional gastrointestinal disorders (FGIDs), or disorders of gut-brain interaction (DGBIs), are gastrointestinal (GI) disorders related to any combination of motility disturbance, visceral hypersensitivity, altered

are the most researched of the FGIDs and the most salient for clinicians: IBS, FD, functional constipation (FC), functional diarrhea, and functional bloating/distention.

The overall aims of this global study were to conduct an extensive multinational epidemiological study of all the FGIDs that are assessable by self-report, to obtain reliable and precise regional and local estimates of FGID prevalence, and to collect data on numerous potentially associated factors that might explain differences in FGIDs among populations and generate hypotheses to advance understanding of their pathophysiology.

Secondary aims included the development of a database that could serve as a source of data mining and be integrated with other similar databases in the future, and to establish a network of FGID experts with a track record of research collaboration on a global scale.

The present paper focuses on classic epidemiological findings: prevalence rates by country and geographical region, by age and sex, and preliminary indicators of burden of disease. As a descriptive study, there are no a priori hypotheses, so no hypothesis testing was conducted.

## Methods

The study was conducted in 33 countries (Figure 1): Argentina, Australia, Bangladesh, Belgium, Brazil, Canada, China, Colombia, Egypt, France, Germany, Ghana, Holland, India, Indonesia, Iran, Israel, Italy, Japan, Malaysia, Mexico, Nigeria, Poland, Romania, Russia, Singapore, South Africa, South Korea, Spain, Sweden, Turkey, the UK, and the US. This country selection, based on the availability of interested country principal investigators, provided a good global coverage, except for Africa (represented only by Egypt, South Africa, Ghana, and Nigeria) and the Middle East, especially Arab countries (Egypt only). As seen in Figure 1, data were collected by Internet survey only in 24 countries, by personal interview only in 7 countries and by both methods in 2 countries (see later in this article).

A minimum of 2000 individuals were surveyed in each country, in both the Internet and household surveys. In India and China, the minimum number of individuals in the surveys was increased to allow for the size of the national populations. In Japan the sample size was raised to 2500 because the sex ratio among the first 2000 participants was higher among men in some age groups. We recruited an additional 500 participants, primarily women, to achieve a more balanced sex ratio. Thus, the final study population was larger than originally anticipated at 70,000 (33 countries with 2000 individuals each, plus double surveys in China and Turkey). The predefined demographic parameters for all countries were 50% female and 50% male individuals, and 40% for 18 to 39 years, 40% for 40 to 64 years, and 20% for 65+ years.

In countries where most adults use the Internet, a secured online survey (accessible only to preselected invited participants) was conducted using population samples provided by a professional company (Qualtrics, LLC, Provo, UT) who awarded participant points redeemable for gifts. These surveys were anonymous, nationwide, and had built-in quality-assurance measures to exclude poor-quality responders, including 2 attention-check questions, a completion-speed check, and repeat questions to detect inconsistent responders. The software

### WHAT YOU NEED TO KNOW

#### BACKGROUND AND CONTEXT

Functional gastrointestinal disorders (FGIDs, or disorders of gut-brain interaction) place an economic burden on healthcare systems and reduce quality of life, but little is known about their worldwide prevalence or distribution.

#### NEW FINDINGS

In a large-scale multi-national study, the authors found that more than 40% of persons worldwide have FGIDs. Similar trends and relative distributions were found in people who completed internet vs personal interviews.

#### LIMITATIONS

Study participants completed questionnaires over the internet or by in-person interviews; further studies of the worldwide prevalence of FGIDs, where possible with confirmation, are indicated.

#### IMPACT


FGIDs are common in all regions of the world. Proportions of persons with irritable bowel syndrome are lower when the Rome IV criteria are used, compared with the Rome III criteria.

ensured that there were no missing answers to compulsory questions, and had automated skip patterns, resulting in complete and accurate symptom pattern information.

In countries in which an Internet survey was unfeasible, usually because of poor Internet coverage, personal interviews were conducted in probability samples of individuals (1 per household) in selected villages and cities, without national representation. The household survey countries were Bangladesh, Ghana, India, Indonesia, Iran, Malaysia, and Nigeria. In the case of Iran, the Internet infrastructure was sufficient for an Internet survey, but Qualtrics, Inc. did not have access to a pool of potential subjects in that country as it did in the other countries where the survey was conducted by Internet. Residents of the participating villages were invited to meetings where the study was explained. They were encouraged by civic and religious community leaders to participate and were offered a 1-time free medical consultation in return. In China and Turkey, we collected data with the household methodology and the Internet survey, resulting in a household survey dataset from a total of 9 different countries. Unlike the other household surveys, the household study in Turkey was conducted nationwide after the Internet study had been completed, so we achieved a similar geographical, sex, and age distribution as the Internet survey, with interview responses captured directly into electronic devices, eliminating the problems with incomplete or missing responses found in other household surveys.

### FGID Case Definitions

The survey included the complete Adult Rome IV Diagnostic Questionnaire<sup>12</sup> and a self-report checklist of organic diseases and surgeries that can cause gastrointestinal symptoms, to identify FGID cases. Twenty-two FGID diagnoses were assigned according to Rome IV criteria, based on responses to the Rome IV Diagnostic Questionnaire. Individuals who otherwise met Rome IV FGID criteria were excluded from FGID case definition



**Figure 1.** Global map showing study countries, colored-coded by data collection method: Internet, household interviews, or both. The Internet survey was conducted in 26 countries and the household survey in 9 countries, 2 (Turkey and China) used both methods, totaling 33 countries in all.

if they self-reported a medical history that could represent organic or structural reasons for the symptoms. For example, subjects reporting celiac disease, GI cancer or inflammatory bowel disease (Crohn's disease or ulcerative colitis) were excluded from all Rome IV FGID diagnoses. Subjects with a history of peptic ulcer disease were excluded from esophageal, gastroduodenal, and biliary diagnoses. Finally, subjects who reported diverticulitis or bowel resection were excluded from bowel and anorectal disorders. Because no independent medical evaluation was done, this exclusion method may have eliminated individuals who did not have a functional GI disorder.

For household countries, where a proportion of cases had missing responses to diagnostic questions on the 22 FGIDs, these cases were excluded from prevalence analysis for all the FGIDs ( $N = 4087$ ) leaving a final total of 18,949. This was necessary because several Rome FGID diagnoses overlap and the determination of whether a person warrants a particular diagnosis may depend on whether criteria for one or more other FGIDs are met.

The survey also included an 80-item supplemental questionnaire on sociodemographic characteristics, medical and health history, comorbid symptoms and conditions, GI infections, health care utilization, medications, childhood and current living conditions, psychosocial variables, diet, QOL, and culture and religion (Supplemental Table 1). It incorporated validated questionnaires, such as the Patient Health Questionnaire-15,<sup>13</sup> IBS symptom severity scale (IBS-SSS),<sup>14</sup> and the Personal Health Questionnaire-4<sup>15</sup> on anxiety and depression.

The Rome III IBS diagnostic questions<sup>16</sup> were included in all 9 household survey countries and in 14 of the 26 Internet countries (Belgium, Brazil, Canada, China, Egypt, France, Germany, Holland, Israel, Japan, Mexico, Russia, Singapore, and Turkey) to compare IBS prevalence between Rome III and Rome IV criteria. The reason we did this for IBS and not for all FGIDs was that its criteria underwent the most substantial change between Rome III and IV and the length of the study questionnaires reached a limit that could not be expanded. Including all the Rome III questions for the other FGIDs would have increased the study questionnaire by about 50%.

We used 2 proxy variables to assess the burden of FGIDs: (1) health care utilization; ie, history of (a) physician consultation about bowel problems and (b) frequency of doctor visits per year for any health problems, and (2) QOL scores on the Patient-Reported Outcomes Measurement Information System (PROMIS) Global-10 questionnaire (range 4–20).<sup>17</sup> As part of the PROMIS, this questionnaire is a publicly available global health assessment tool that measures symptoms, functioning, and health care-related QOL for a wide variety of chronic diseases and conditions.

The study questionnaire underwent translatability assessment by a professional company (TransPerfect, Inc, New York, NY),<sup>18</sup> and was then translated by the same company into 21 languages with linguistic validation (cognitive debriefing). Each country principal investigator monitored this process to ensure that the translated questionnaires were linguistically valid and culturally adapted for their country. Where appropriate, the translations were "localized," for example, the original English

**Table 1.** Pooled Prevalence Rates (% and 95% CI) for 22 Rome IV FGIDs, in a Combined Population-based Internet Survey Sample of 54,127 Individuals in 26 Countries and in a Combined Household Survey Sample of 18,949 Individuals in 9 Countries


FGID	Overall N = 54,127	Sex		Age group (y)		
		Female n = 26,578	Male n = 27,549	18–39 n = 23,003	40–64 n = 22,281	65+ n = 8843
Internet						
Any FGID	40.3 (39.9–40.7)	46.5 (45.9–47.1)	34.2 (33.7–34.8)	44.3 (43.7–44.9)	39.4 (38.8–40.1)	31.9 (30.9–32.8)
A. Esophageal Disorders						
Functional chest pain	1.4 (1.3–1.5)	1.5 (1.3–1.6)	1.3 (1.1–1.4)	1.4 (1.3–1.6)	1.5 (1.3–1.6)	1.0 (0.8–1.3)
Functional heartburn	1.1 (1.0–1.2)	1.3 (1.1–1.4)	1.0 (0.9–1.1)	1.3 (1.1–1.4)	1.2 (1.0–1.3)	0.7 (0.5–0.8)
Reflux hypersensitivity	0.8 (0.8–0.9)	0.9 (0.8–1.0)	0.8 (0.7–0.9)	0.9 (0.7–1.0)	1.0 (0.8–1.1)	0.5 (0.4–0.6)
Globus	0.8 (0.7–0.8)	0.9 (0.7–1.0)	0.7 (0.6–0.8)	0.8 (0.6–0.9)	0.9 (0.7–1.0)	0.5 (0.4–0.7)
Functional dysphagia	3.2 (3.0–3.3)	3.5 (3.3–3.7)	2.9 (2.7–3.1)	3.3 (3.1–3.5)	3.2 (3.0–3.4)	2.7 (2.4–3.0)
<i>Any esophageal disorder</i>	6.0 (5.8–6.2)	6.6 (6.3–6.9)	5.4 (5.1–5.6)	6.2 (5.9–6.5)	6.3 (6.0–6.6)	4.6 (4.2–5.0)
B. Gastroduodenal Disorders						
Functional dyspepsia	7.2 (7.0–7.4)	8.7 (8.4–9.1)	5.8 (5.5–6.0)	9.2 (8.8–9.5)	6.6 (6.2–6.9)	3.8 (3.4–4.2)
PDS	6.1 (5.9–6.3)	7.5 (7.2–7.8)	4.8 (4.6–5.1)	7.8 (7.5–8.2)	5.5 (5.2–5.8)	3.3 (2.9–3.6)
EPS	2.4 (2.3–2.5)	2.8 (2.6–3.0)	2.0 (1.8–2.2)	2.9 (2.7–3.1)	2.4 (2.2–2.6)	1.2 (0.9–1.4)
Belching disorder	1.0 (0.9–1.1)	1.1 (1.0–1.2)	0.9 (0.7–1.0)	1.1 (1.0–1.2)	1.0 (0.8–1.1)	0.7 (0.5–0.8)
Rumination syndrome	2.8 (2.7–2.9)	3.1 (2.9–3.3)	2.5 (2.3–2.7)	2.7 (2.5–2.9)	3.0 (2.8–3.2)	2.4 (2.1–2.7)
Chronic nausea vomiting syndrome	0.9 (0.8–1.0)	1.2 (1.0–1.3)	0.7 (0.6–0.8)	1.3 (1.2–1.5)	0.7 (0.6–0.8)	0.4 (0.3–0.5)
Cyclic vomiting syndrome	1.2 (1.1–1.2)	1.2 (1.1–1.3)	1.1 (1.0–1.2)	1.6 (1.4–1.8)	0.9 (0.8–1.0)	0.6 (0.5–0.8)
Cannabinoid hyperemesis syndrome	0.05 (0.03–0.07)	0.02 (0.01–0.04)	0.08 (0.05–0.11)	0.11 (0.07–0.15)	0.010 (0.00–0.02)	0.01 (0.00–0.03)
<i>Any gastroduodenal disorder</i>	10.6 (10.4–10.9)	12.4 (12.0–12.8)	8.9 (8.6–9.2)	13.0 (12.5–13.4)	9.8 (9.4,10.2)	6.6 (6.1–7.2)
C. Bowel Disorders						
Rome-IV IBS	4.1 (3.9–4.2)	5.2 (5.0–5.5)	2.9 (2.7–3.1)	5.3 (5.0–5.6)	3.7 (3.5–4.0)	1.7 (1.4–1.9)
IBS-C	1.3 (1.2–1.4)	1.8 (1.7–2.0)	0.8 (0.7–0.9)	1.8 (1.6–2.0)	1.1 (1.0–1.2)	0.6 (0.4–0.8)
IBS-D	1.2 (1.1–1.3)	1.3 (1.2–1.5)	1.0 (0.9–1.1)	1.1 (0.9–1.2)	0.5 (0.3–0.6)	0.5 (0.3–0.6)
IBS-U	0.3 (0.2–0.3)	0.3 (0.2–0.4)	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.3 (0.2–0.3)	0.1 (0.0–0.2)
IBS-M	1.3 (1.2–1.4)	1.8 (1.6–1.9)	0.9 (0.8–1.0)	1.6 (1.5–1.8)	1.3 (1.2–1.5)	0.5 (0.3–0.6)
Functional Constipation	11.7 (11.4–12.0)	15.2 (14.8–15.7)	8.3 (8.0–8.6)	13.2 (12.8–13.7)	11.0 (10.6–11.4)	9.4 (8.8–10.0)
Opioid-induced constipation	1.6 (1.5–1.7)	1.8 (1.6–1.9)	1.4 (1.2–1.5)	1.5 (1.3–1.7)	1.6 (1.5–1.8)	1.5 (1.3–1.8)
Functional diarrhea	4.7 (4.5–4.9)	4.1 (3.8–4.3)	5.3 (5.1–5.6)	4.6 (4.3–4.9)	5.1 (4.8–5.3)	4.1 (3.7–4.5)
Functional bloating/distention	3.5 (3.3–3.6)	4.6 (4.3–4.8)	2.4 (2.2–2.5)	3.4 (3.2–3.7)	3.9 (3.6–4.1)	2.4 (2.1–2.7)
Unspecified functional bowel disorder	8.8 (8.6–9.0)	9.5 (9.1–9.8)	8.1 (7.8–8.5)	9.5 (9.1–9.9)	8.7 (8.3–9.1)	7.2 (6.7–7.7)
<i>Any bowel disorder</i>	33.4 (33.0–33.8)	39.3 (38.7–39.9)	27.7 (27.2–28.2)	36.7 (36.1–37.3)	33.0 (32.4–33.6)	25.9 (24.9–26.8)
D. Central Nervous System Disorders of GI Pain						
Centrally mediated abdominal pain syndrome	0.02 (0.01–0.03)	0.03 (0.01–0.06)	0.00 <sup>a</sup>	0.03 (0.01–0.05)	0.01 (0.00–0.02)	0.01 (0.00–0.03)
E. Biliary Disorders						
Functional biliary pain	0.08 (0.06–0.11)	0.14 (0.09–0.18)	0.03 (0.01–0.04)	0.13 (0.08–0.18)	0.05 (0.02–0.08)	0.02 (0.00–0.05)
F. Anorectal Disorders						
Fecal incontinence	1.6 (1.5–1.7)	1.5 (1.4–1.7)	1.6 (1.5–1.8)	1.1 (1.0–1.3)	1.7 (1.6–1.9)	2.3 (2.0–2.7)
Levator ani syndrome	1.1 (1.1–1.2)	1.4 (1.2–1.5)	0.9 (0.8–1.0)	1.3 (1.2–1.5)	1.2 (1.1–1.4)	0.6 (0.4–0.7)
Proctalgia fugax	5.6 (5.4–5.8)	6.4 (6.1–6.7)	4.7 (4.5–5.0)	6.1 (5.8–6.4)	5.7 (5.4–6.0)	3.9 (3.5–4.3)
<i>Any anorectal disorder</i>	7.7 (7.5–8.0)	8.8 (8.5–9.2)	6.7 (6.4–7.0)	8.0 (7.6–8.3)	8.0 (7.6–8.3)	6.4 (5.9–6.9)
Household						

**Table 1.** Continued

FGID	Overall N = 54,127	Sex		Age group (y)		
		Female n = 26,578	Male n = 27,549	18–39 n = 23,003	40–64 n = 22,281	65+ n = 8843
Any FGID	20.7 (20.2–21.3)	23.1 (22.3–23.9)	18.3 (17.5–19.0)	16.9 (16.1–17.7)	20.7 (19.9–21.6)	30.4 (28.9–32.0)
A. Esophageal Disorders						
Functional chest pain	1.0 (0.9–1.2)	1.2 (1.0–1.4)	0.8 (0.7–1.0)	0.7 (0.5–0.9)	1.2 (1.0–1.5)	1.2 (0.8–1.6)
Functional heartburn	0.4 (0.3–0.4)	0.5 (0.3–0.6)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.4 (0.3–0.6)	0.6 (0.3–0.8)
Reflux hypersensitivity	0.6 (0.5–0.7)	0.8 (0.6–1.0)	0.4 (0.3–0.5)	0.4 (0.2–0.5)	0.7 (0.5–0.8)	0.9 (0.6–1.3)
Globus	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.3 (0.2–0.4)	0.3 (0.1–0.4)
Functional dysphagia	1.2 (1.0–1.3)	1.5 (1.2–1.7)	0.9 (0.7–1.1)	0.6 (0.5–0.8)	1.0 (0.8–1.2)	2.9 (2.4–3.5)
Any esophageal disorder	2.9 (2.7–3.2)	3.6 (3.2–3.9)	2.3 (2.0–2.6)	1.9 (1.6–2.2)	3.1 (2.8–3.5)	4.9 (4.2–5.7)
B. Gastroduodenal Disorders						
Functional dyspepsia	4.8 (4.5–5.1)	5.5 (5.0–5.9)	4.1 (3.7–4.5)	3.2 (2.8–3.5)	4.7 (4.2–5.1)	9.2 (8.3,10.2)
PDS	3.5 (3.2–3.7)	3.8 (3.4–4.2)	3.1 (2.7–3.4)	2.2 (1.9–2.5)	3.2 (2.8–3.6)	7.4 (6.5–8.3)
EPS	1.9 (1.7–2.1)	2.4 (2.1–2.7)	1.4 (1.2–1.7)	1.3 (1.1–1.6)	2.1 (1.8–2.5)	3.0 (2.4–3.6)
Belching disorder	0.7 (0.5–0.8)	0.8 (0.6–1.0)	0.5 (0.4–0.7)	0.5 (0.4–0.7)	0.6 (0.4–0.8)	1.1 (0.8–1.5)
Rumination syndrome	1.1 (0.9–1.2)	1.4 (1.2–1.7)	0.8 (0.6–0.9)	0.9 (0.7–1.1)	1.1 (0.8–1.3)	1.6 (1.2–2.1)
Chronic nausea vomiting syndrome	0.5 (0.4–0.6)	0.6 (0.4–0.7)	0.4 (0.2–0.5)	0.4 (0.2–0.5)	0.4 (0.3–0.6)	0.8 (0.5–1.1)
Cyclic vomiting syndrome	0.3 (0.3–0.4)	0.5 (0.3–0.6)	0.2 (0.1–0.3)	0.3 (0.2–0.4)	0.4 (0.2–0.5)	0.5 (0.2–0.7)
Cannabinoid hyperemesis syndrome	0.01 (0.00–0.02)	0.00 <sup>a</sup>	0.01 (0.00–0.03)	0.01 (0.00–0.04)	0.00 <sup>a</sup>	0.00 <sup>a</sup>
Any gastroduodenal disorder	6.3 (6.0–6.6)	7.3 (6.8–7.8)	5.2 (4.8–5.7)	4.5 (4.0–4.9)	6.1 (5.6–6.7)	11.3 (10.3,12.4)
C. Bowel Disorders						
Rome-IV IBS	1.5 (1.3–1.7)	2.0 (1.7–2.3)	1.0 (0.8–1.2)	1.4 (1.1–1.7)	1.5 (1.2–1.7)	1.9 (1.4–2.4)
IBS-C	0.6 (0.5–0.7)	0.8 (0.6–1.0)	0.3 (0.2–0.4)	0.4 (0.3–0.5)	0.6 (0.4–0.7)	1.0 (0.6–1.3)
IBS-D	0.4 (0.3–0.5)	0.5 (0.4–0.6)	0.4 (0.2–0.5)	0.5 (0.3–0.6)	0.4 (0.3–0.6)	0.3 (0.1–0.4)
IBS-U	0.2 (0.2–0.3)	0.3 (0.2–0.4)	0.2 (0.1–0.3)	0.3 (0.2–0.4)	0.2 (0.1–0.3)	0.2 (0.0–0.3)
IBS-M	0.3 (0.2–0.3)	0.4 (0.2–0.5)	0.2 (0.1–0.2)	0.2 (0.1–0.3)	0.2 (0.1–0.3)	0.5 (0.2–0.7)
Functional Constipation	6.6 (6.3–6.9)	7.4 (6.9–7.9)	5.8 (5.4–6.3)	5.2 (4.7–5.6)	6.3 (5.8–6.8)	11.1 (10.0,12.1)
Opioid-induced constipation	0.9 (0.7–1.0)	1.0 (0.8–1.2)	0.8 (0.6–0.9)	0.5 (0.4–0.7)	0.8 (0.6–1.0)	1.9 (1.4–2.4)
Functional diarrhea	1.2 (1.0–1.3)	1.1 (0.9–1.3)	1.3 (1.0–1.5)	0.9 (0.7–1.1)	1.2 (1.0–1.5)	1.7 (1.3–2.2)
Functional bloating/distention	1.2 (1.0–1.3)	1.3 (1.1–1.5)	1.1 (0.9–1.3)	1.1 (0.8–1.3)	1.4 (1.1–1.6)	1.0 (0.7–1.4)
Unspecified functional bowel disorder	4.9 (4.6–5.2)	5.3 (4.9–5.8)	4.4 (4.0–4.8)	4.3 (3.9–4.8)	4.9 (4.4–5.3)	6.2 (5.4–7.1)
Any bowel disorder	16.0 (15.5–16.5)	17.7 (17.0–18.5)	14.2 (13.5–14.9)	13.2 (12.4–13.9)	15.9 (15.1–16.7)	23.4 (22.0–24.9)
D. Central Nervous System Disorders of GI Pain						
Centrally mediated abdominal pain syndrome	0.05 (0.02–0.08)	0.05 (0.01–0.10)	0.04 (0.00–0.08)	0.06 (0.01–0.12)	0.03 (0.00–0.06)	0.06 (0.00–0.15)
E. Biliary Disorders						
Functional biliary pain	0.03 (0.00–0.05)	0.04 (0.00–0.08)	0.01 (0.00–0.03)	0.00 <sup>a</sup>	0.00 <sup>a</sup>	0.16 (0.02–0.30)
F. Anorectal Disorders						
Fecal incontinence	0.4 (0.4–0.5)	0.5 (0.4–0.7)	0.4 (0.2–0.5)	0.2 (0.1–0.3)	0.4 (0.3–0.5)	1.2 (0.8–1.6)
Levator ani syndrome	0.7 (0.6–0.8)	0.9 (0.7–1.1)	0.5 (0.3–0.6)	0.4 (0.3–0.6)	0.7 (0.5–0.9)	1.3 (0.9–1.7)
Proctalgia fugax	1.5 (1.4–1.7)	1.8 (1.6–2.1)	1.3 (1.0–1.5)	1.3 (1.0–1.5)	1.8 (1.5–2.1)	1.6 (1.2–2.1)
Any anorectal disorder	2.6 (2.3–2.8)	3.2 (2.8–3.5)	2.0 (1.7–2.2)	1.8 (1.5–2.1)	2.8 (2.5–3.2)	3.8 (3.1–4.4)

<sup>a</sup>No cases

# Any FGID



CLINICAL AT

**Figure 2.** Global maps showing study countries (Internet above, household below), color-coded for prevalence of having any FGID.

questionnaire was translated into Spanish for Mexico and then localized for Colombia, Argentina, and Spain.

### Statistical Considerations

In a descriptive study, when estimating prevalence rates, sample size considerations are guided by the desired precision in the 95% confidence intervals. When estimating unknown prevalence rates, the most conservative approach (ie, the one that provides the largest variance and thus the widest confidence intervals), assumes a prevalence of 0.50. In this study, we chose the minimum sample size of 2000 participants per country to obtain high precision of within-country estimates of prevalence rates. Thus, 95% confidence intervals for prevalence rates as high as 0.50 would range within  $\pm 0.022$ ; and less common diagnoses (smaller prevalence rates) would have higher precision (narrower confidence intervals).

We calculated country-specific prevalence rates for all major FGID diagnoses by sex and age groups. Prevalence rates were pooled across countries using Yang’s meta-prevalence method,<sup>19</sup> which combines separate population survey prevalence estimates into an overall meta-prevalence estimate. Because of substantial differences in data collection methodology between the Internet and household methods, global pooling was done within survey type only.

Ethical review was completed for all countries. The study was approved or exempted from ethics board oversight (the latter for Internet survey countries, where subjects were anonymous to the investigators). All survey participants completed a written consent form, either electronically (Internet surveys) or on paper (household surveys).

### Results

The survey was completed by 73,076 respondents; 36,148 women (49.5%) and 36,928 men (50.5%). The numbers of women by survey group were 26,576 respondents (49.1%) in the Internet countries and 18,949 (50.5%) in the household countries. We successfully achieved equal sex distribution and pre-planned age ranges in most countries with both surveying methods.


We do not have full data on response rates. In the Internet surveys, panels of registered country-specific survey-takers were contacted through e-mail until all quota categories were filled. There is no way to know how many saw those e-mails or how many were reached, so response rates are not available.

We have full response rates for Bangladesh, Malaysia, both surveyed regions in India, and Iran but the number of subjects approached in the other household sites was not

**Table 2.** Prevalence Rates (% and 95% CI) for 5 Selected Major Functional Gastrointestinal Diagnoses (Rome IV)– for Any FGID (26 Countries) and Rome III IBS (14 Countries) in the Internet Survey and for All 9 Countries in the Household Survey

	N	Any FGID	Functional Dyspepsia	IBS (Rome IV)	IBS (Rome III) (N=14)	Functional Constipation	Functional Diarrhea	Functional bloating/distention
<b>INTERNET</b>								
Argentina	2057	43.9 (41.8–46.1)	6.9 (5.8–8.0)	3.5 (2.7–4.3)	N/A	12.2 (10.7–13.6)	6.3 (5.2–7.3)	5.2 (4.2–6.1)
Australia	2036	37.6 (35.5–39.7)	7.2 (6.0–8.3)	3.5 (2.7–4.3)	N/A	7.7 (6.6–8.9)	5.1 (4.1–6.0)	4.2 (3.3–5.0)
Belgium	2021	35.6 (33.5–37.7)	5.0 (4.0–5.9)	3.3 (2.5–4.0)	7.5 (6.4–8.7)	11.0 (9.7–12.4)	4.0 (3.2–4.9)	2.4 (1.7–3.0)
Brazil	2004	43.6 (41.4–45.8)	10.6 (9.2–11.9)	4.7 (3.8–5.6)	8.3 (7.1–9.5)	11.9 (10.5–13.3)	4.8 (3.9–5.7)	2.7 (2.0–3.5)
Canada	2029	41.3 (39.1–43.4)	7.8 (6.7–9.0)	4.2 (3.3–5.1)	10.12 (8.8–11.4)	9.3 (8.0–10.5)	7.6 (6.4–8.7)	3.3 (2.5–4.1)
China	2914	34.4 (32.7–36.1)	5.9 (5.0–6.7)	2.3 (1.8–2.9)	7.4 (6.5–8.4)	10.6 (9.5–11.7)	5.6 (4.8–6.5)	0.7 (0.4–1.0)
Colombia	2007	42.5 (40.3–44.7)	7.2 (6.0–8.3)	4.3 (3.4–5.2)	N/A	12.8 (11.3–14.2)	4.1 (3.2–5.0)	4.5 (3.6–5.4)
Egypt	2020	47.7 (45.5–49.9)	12.3 (10.8–13.7)	7.6 (6.4–8.7)	14.0 (12.4–15.59)	14.1 (12.6–15.6)	2.2 (1.6–2.9)	3.2 (2.4–3.9)
France	2019	47.3 (45.1–49.5)	8.5 (7.3–9.7)	4.2 (3.3–5.0)	9.8 (8.5–11.1)	14.5 (12.6–16.1)	6.1 (5.1–7.2)	6.0 (5.0–7.0)
Germany	2020	36.5 (34.4–38.6)	6.9 (5.8–8.0)	3.7 (2.8–4.5)	11.1 (9.8–12.5)	9.8 (7.9–10.5)	5.4 (4.4–6.4)	2.8 (2.1–3.5)
Holland	2008	30.6 (28.6–32.6)	4.1 (3.2–5.0)	3.8 (2.9–4.6)	9.7 (8.4–11.0)	9.2 (7.9–10.5)	3.2 (2.5–4.0)	1.5 (1.0–2.0)
Israel	2012	36.4 (34.3–38.5)	3.6 (2.8–4.4)	3.2 (2.5–4.0)	12.8 (11.4–14.3)	13.1 (11.6–14.6)	2.4 (1.8–3.1)	2.1 (1.5–2.7)
Italy	2063	47.2 (45.1–49.4)	9.1 (7.8–10.3)	5.0 (4.1–5.9)	N/A	14.4 (12.7–15.8)	3.2 (2.5–4.0)	8.2 (7.1–9.4)
Japan	2504	39.4 (37.5–41.3)	2.4 (1.8–3.0)	2.2 (1.6–2.7)	9.3 (8.2–10.4)	16.6 (15.1–18.0)	5.2 (4.3–6.0)	1.2 (0.8–1.6)
South Korea	2022	39.3 (37.2–41.4)	4.9 (4.0–5.9)	4.7 (3.8–5.6)	N/A	12.5 (11.0–13.9)	5.8 (4.8–6.8)	2.1 (1.5–2.8)
Mexico	2001	40.2 (38.0–42.3)	6.6 (5.5–7.7)	4.0 (3.2–4.9)	12.6 (11.1–14.0)	11.5 10.1–12.9)	4.4 (3.5–5.3)	3.4 (2.6–4.2)
Poland	2057	46.0 (43.9–48.2)	8.3 (7.1–9.5)	4.4 (3.5–5.3)	N/A	14.2 (12.7–15.8)	4.5 (3.6–5.4)	5.3 (4.3–6.3)
Romania	2049	40.1 (38.1–42.2)	7.4 (6.3–8.6)	3.5 (2.7–4.3)	N/A	11.7 (10.3–13.1)	2.6 (1.9–3.3)	6.7 (5.6–7.8)
Russia	2000	44.6 (42.4–46.8)	10.3 (9.0–11.6)	5.9 (4.8–6.9)	16.5 (14.9–18.1)	11.6 (10.1–13.0)	7.1 (6.0–8.2)	2.6 (1.9–3.2)
Singapore	2047	31.1 (29.1–33.1)	5.9 (4.9–6.9)	1.3 (0.8–1.8)	4.3 (3.4–5.1)	9.5 (8.2–10.7)	4.3 (3.4–5.1)	3.6 (2.8–4.4)
South Africa	2021	45.2 (43.0–47.3)	11.0 (9.7–12.4)	5.9 (4.9–7.0)	N/A	11.1 (9.7–12.5)	5.1 (4.2–6.1)	4.2 (3.3–5.1)
Spain	2072	43.7 (41.6–45.9)	7.4 (6.3–8.5)	4.2 (3.4–5.1)	N/A	12.8 (11.4–14.3)	4.8 (3.9–5.7)	3.4 (2.6–4.2)
Sweden	2084	39.0 (36.9–41.1)	8.2 (7.0–9.4)	4.0 (3.1–4.8)	N/A	10.3 (9.0–11.6)	5.9 (4.8–6.9)	3.1 (2.4–3.9)
Turkey	2010	39.7 (37.6–41.8)	5.3 (4.3–6.3)	3.9 (3.1–4.8)	9.8 (8.5–11.1)	14.1 (12.6–15.6)	2.5 (1.8–3.2)	3.0 (2.2–3.7)
USA	2023	39.9 (37.8–42.0)	10.1 (8.8–11.4)	5.3 (4.4–6.3)	N/A	8.7 (7.5–10.0)	5.0 (4.1–6.0)	2.0 (1.4–2.6)
UK	2027	36.7 (34.6–38.8)	6.6 (5.5–7.6)	4.0 (3.1–4.8)	N/A	8.6 (7.4–9.8)	4.5 (3.6–5.4)	3.8 (3.0–4.7)
<b>Pooled overall prevalence</b>	<b>54127</b>	<b>40.3 (39.9–40.7)</b>	<b>7.2 (7.0–7.4)</b>	<b>4.1 (3.9–4.2)</b>	<b>10.1 (9.8–10.5)</b>	<b>10.1 (11.4–12.0)</b>	<b>4.7 (4.5–4.9)</b>	<b>3.5 (3.3–3.6)</b>
<b>HOUSEHOLD</b>								
Bangladesh	2018	40.0 (37.9–42.2)	19.4 (17.7–21.2)	4.6 (3.7–5.5)	10.7 (9.3–12.0)	11.8 (10.4–13.2)	2.1 (1.5–2.8)	2.2 (1.6–2.9)
China	2710	22.7 (21.1–24.2)	4.3 (3.6–5.1)	1.4 (1.0–1.8)	3.8 (3.1–4.5)	6.2 (5.3–7.1)	2.6 (2.0–3.2)	1.3 (0.8–1.7)
Ghana	1190	45.0 (42.2–47.9)	7.2 (5.8–8.7)	0.3 (0.0–0.7)	0.4 (0.1–0.8)	26.1 (23.6–28.6)	0.7 (0.2–1.1)	0.0
India	4592	7.2 (6.5–8.0)	0.7 (0.5–1.0)	0.2 (0.1–0.3)	0.4 (0.2–0.6)	1.8 (1.4–2.2)	0.2 (0.1–0.4)	0.2 (0.1–0.3)
Indonesia	1231	19.0 (16.8–21.2)	4.4 (3.2–5.5)	3.5 (2.5–4.5)	6.2 (4.8–7.5)	3.5 (2.5–4.5)	1.1 (0.5–1.6)	1.1 (0.5–1.6)
Iran	1840	27.2 (25.2–29.3)	2.9 (2.1–3.6)	2.1 (1.4–2.7)	4.6 (3.6–5.5)	11.0 (9.5–12.4)	1.3 (0.7–1.8)	5.1 (4.1–6.1)
Malaysia	1976	19.7 (18.0–21.5)	3.3 (2.5–4.1)	0.7 (0.3–1.1)	3.9 (3.1–4.8)	5.4 (4.4–6.4)	1.7 (1.1–2.3)	0.9 (0.5–1.3)
Nigeria	1442	25.1 (22.9–27.3)	6.0 (4.8–7.3)	2.7 (1.9–3.5)	5.1 (3.8–6.4)	4.3 (3.3–5.3)	0.9 (0.4–1.4)	0.3 (0.0–0.7)
Turkey	1950	7.6 (6.5–8.8)	1.1 (0.6–1.5)	0.4 (0.1–0.7)	0.9 (0.5–1.3)	1.9 (1.3–2.6)	0.4 (0.1–0.6)	0.5 (0.2–0.8)
<b>Pooled overall prevalence</b>	<b>18949</b>	<b>20.7 (20.2–21.3)</b>	<b>4.8 (4.5–5.1)</b>	<b>1.5 (1.3–1.7)</b>	<b>3.5 (3.3–3.8)</b>	<b>6.6 (6.3–6.9)</b>	<b>1.2 (1.0–1.3)</b>	<b>1.2 (1.0–1.3)</b>





**Figure 3.** Distribution of country-specific (*circles*) and pooled (*boxes*) prevalence rates for 5 selected major FGIDs in the countries surveyed by Internet (N = 26) and household interviews (N = 9) with Rome IV criteria.

tracked comprehensively. In Bangladesh the response rate was 99.5%, in Malaysia 92.8%, in northern India 99.2%, in southern India 99.0%, and in Iran 97.8%.

The sample demographics, by survey method, appear in [Supplemental Table 2](#). All Internet survey countries met the minimum sample size ( $\geq 2000$ ) and equal sex (50%:50%) parameters. In 6 Internet countries, the age group distribution was not fully met due to the inability to enroll sufficient numbers in the 65+ age group. In these countries, there is limited Internet access or lower usage. In Egypt, women were underrepresented, possibly due to lower Internet use or culture. Based on the US Census Bureau classification for rural communities (fewer than 2500 residents),<sup>20</sup> 9.7% of the participants lived in rural communities in Internet countries and 43.3% in household countries.

The household surveys achieved the minimum target sample size of at least 2000 completed interviews, but the quality of the data were lower than in the Internet survey, particularly in Ghana (1190 records valid for analysis), Indonesia (1231), and Nigeria (1442). The total number of respondents who would have met the criteria for FGID diagnoses but were classified as non-FGID due to reporting organic diseases or a GI surgery was 4094 (7.6%) in Internet surveys and 748 (4.0%) in household surveys.

The prevalence results are presented below in accordance with GI tract anatomic regions, corresponding to the order of the questions in the Rome IV Diagnostic Questionnaire. The results for all the FGIDs appear in [Table 1](#). These results are discussed in a more comprehensive and overlapping context in the Discussion section, later in this article. The country distribution of having any FGID is shown in [Figure 2](#).

The prevalence rates of 5 selected major FGIDs compared across all the countries surveyed are shown in

[Table 2](#) and [Figure 3](#), to provide a more detailed view of the variance of these disorders globally.

### Esophageal Disorders

The most prevalent esophageal disorder in Internet and household surveys was functional dysphagia, with pooled prevalence rates of 3.2% (3.0%–3.3%) and 1.2% (1.0%–1.3%), respectively. The rates for functional heartburn, reflux hypersensitivity, and esophageal chest pain were substantially lower. All esophageal disorders were more prevalent among women in both survey methods. However, there was a divergence in results in terms of age, with decreasing rates in the older age groups in the Internet countries but increasing rates with age in the household countries.

### Gastroduodenal Disorders

FD was the most prevalent gastroduodenal disorder, with a pooled prevalence rate of 7.2% (7.1%–7.4%) for Internet and 4.8% (4.5%–5.1%) for household surveys. In the Internet surveys, the subtype distribution was 66.6% postprandial distress syndrome (PDS), 15.3% epigastric pain syndrome (EPS), and 18.1% overlapping PDS/EPS. In the household countries, the subtype distribution was 59.5% PDS, 28.1% EPS and 12.4% overlapping PDS/EPS. FD rates varied widely between countries, from 2.2% in Japan to 12.3% in Egypt in the Internet surveys and from 0.7 (0.5–1.0) in India to 19.4 (17.7–21.2) in Bangladesh in the household surveys.

Women had higher mean FD rates in the Internet surveys than men, with an odds ratio (OR) of 1.6 (1.5–1.7) for overall FD, 1.6 for PDS (1.5–1.7), and 1.4 (1.3–1.6) for EPS. FD and its 2 subtypes were most common among young

**Table 3.** A Comparison of Pooled Prevalence Rates (% and 95% CI) for Rome III and Rome IV Diagnostic Criteria for IBS in 14 Internet Countries (N = 29,606) and 9 Household Countries (N = 18,949)

FGID	Overall	Sex		Age group (y)		
		Female	Male	18–39	40–64	65+
Internet						
Rome IV IBS	3.8 (3.6–4.0)	4.8 (4.4–5.1)	2.9 (2.6–3.1)	4.9 (4.5–5.3)	3.3 (3.0–3.6)	1.9 (1.6–2.3)
Rome III IBS	10.1 (9.8–10.5)	12.6 (12.1–13.2)	7.8 (7.3–8.2)	11.5 (11.0–12.1)	9.7 (9.1–10.2)	7.5 (6.78–8.2)
Household						
Rome IV IBS	1.5 (1.3–1.7)	2.0 (1.7–2.3)	1.0 (0.8–1.2)	1.4 (1.1–1.7)	1.5 (1.2–1.7)	1.9 (1.4–2.4)
Rome III IBS	3.5 (3.3–3.81)	4.1 (3.7–4.5)	3.0 (2.6–3.3)	2.9 (2.5–3.2)	3.4 (3.0–3.8)	5.5 (4.7–6.3)

adults and decreased steadily in prevalence across the adult life span.

### Functional Bowel Disorders

The most prevalent bowel disorder in both survey types was FC, with pooled rates of 11.7% (11.4%–12.0%) and 6.6% (6.3%–6.9%) for Internet and household surveys, respectively. Other prevalent disorders were functional diarrhea at 4.7% (4.5%–4.9%) and 1.2% (1.0%–1.3%), IBS at 4.1% (3.9%–4.2%) and 1.5% (1.3%–1.7%), and functional abdominal bloating/distention at 3.5% (3.3%–3.6%) and 1.2% (1.0%–1.3%), respectively.

The prevalence rates of IBS among Internet survey countries ranged from a low of 1.3% (0.8%–1.8%) in Singapore to 7.6% (6.4%–8.7%) in Egypt (Table 2 and Figure 3). However, most of the countries (19 of 26) had IBS rates between 3% and 5%. The outliers besides Singapore and Egypt were Japan (2.2%), China (2.3%), Russia (5.9%), South Africa (5.9%), and the United States (5.3%). Twenty-four of the 26 countries had prevalence rates between 2% and 6%, with Singapore and Egypt as outliers. In the household countries, IBS prevalence ranged from 0.2% (0.1%–0.3%) in India to 4.6% (3.7%–5.5%) in Bangladesh, and the variance was greater than in the Internet countries (Table 2 and Figure 3). The pooled prevalence rates for IBS were substantially higher among women in both survey methods, with a female-to-male OR of 1.8 (1.7–2.0) for the Internet and 2.0 (1.5–2.5) for the household countries. IBS prevalence decreased with age in the Internet surveys, from 5.3% (5.0%–5.6%) to 3.7% (3.5%–4.0%) to 1.7% (1.4%–1.9%), whereas it increased with age in the household group from 1.4% (1.1%–1.7%) to 1.5% (1.2%–1.7%) to 1.9% (1.4%–2.4%).

As a group, the functional bowel disorders were the most prevalent of all GI regions, with 33.4% (33.0%–33.8%) of the 54,127 Internet participants and 16.0% (15.5%–16.5%) of the 18,949 household participants having at least 1 of those 6 disorders.

### Centrally Mediated Abdominal Pain Syndrome and Biliary Pain

There were almost no cases of either of these diagnostic entities. The rate for centrally mediated abdominal pain syndrome

was 0.02% (n = 9) for the Internet survey and 0.05% (n = 9) for the household survey. The corresponding rates for biliary pain were 0.08% (n = 44) and 0.03% (n = 5), respectively.

### Anorectal Disorders

In the Internet surveys, 7.7% (7.5%–8.0%) of subjects met criteria for at least one anorectal disorder, compared with 2.6% (2.3%–2.8%) in the household surveys. In both cases, the most prevalent disorder was proctalgia fugax at 5.6% (5.4%–5.8%) in the Internet surveys and 1.5% (1.4%–1.7%) in the household surveys.

### Comparison of IBS Prevalence by Rome IV and Rome III Diagnostic Criteria

In the 14 Internet countries where Rome III questions were included, the overall IBS prevalence was 3.8% (3.6%–4.0%) by Rome IV criteria and 10.1% (9.8%–10.5%) by Rome III criteria (Table 3). Rome IV IBS rates were substantially lower than Rome III in all countries, ranging from 24% to 57% of Rome III IBS prevalence rates. In the 9 household countries, the pooled IBS prevalence rates were 1.5% (1.3%–1.7%) using Rome IV and 3.5% (3.3%–3.8%) using Rome III, with Rome IV prevalence rates ranging from 18% to 75% of Rome III IBS prevalence rates. In this group of countries, the prevalence increased for both criteria with increasing age.

In contrast to the household surveys, by both criteria, IBS rates were lower on average in older individuals in the Internet surveys. Women had substantially higher IBS rates than men in all age groups by both criteria: Rome III OR 1.7 (1.6–1.9) and Rome IV OR 1.7 (1.5–1.9).

The overall Rome IV IBS subtype distribution was 28.7% IBS-D, 32.4% IBS-C, 32.4% IBS-M, and 6.5% IBS-U in the 26 Internet countries, and 28.8% IBS-D, 37.9% IBS-C, 17.2% IBS-M, and 16.1% IBS-U in the 9 household countries.

Individuals with Rome IV IBS had higher mean IBS-SSS severity scores, 250 (244–256) vs Rome III IBS 191 (187–194), in the Internet countries. In the household countries, individuals with Rome IV IBS had an IBS-SSS severity score of 174 (158–190) vs Rome III IBS 134 (124–144).

### Burden of FGIDs

In the Internet surveys, individuals with FGIDs were more likely than others to be high-frequency medical

**Table 4.** Comparison of PROMIS-10 Quality of Life Scores (Physical And Mental) for Patients With and Without at Least One FGID– and Rates of Doctor Visits for Bowel and Any Other Health Problems in the 26 Internet Survey Countries and in the 9 Household Survey Countries

	N	PROMIS-10 Physical (mean, 95% CI)		PROMIS-10 Mental (mean, 95% CI)		Has visited a doctor for bowel problem (% , 95% CI)		One or more doctor visits/month for any health problem (% , 95% CI)	
		Any FGID	No FGID	Any FGID	No FGID	Any FGID	No FGID	Any FGID	No FGID
<b>INTERNET</b>									
Pooled Estimates	<b>54127</b>	13.5 (13.4–13.5)	15.2 (15.1–15.2)	12.5 (12.5–12.6)	14.2 (14.2–14.3)	46.5 (45.9–47.2)	27.1 (26.6–27.5)	15.5 (15.1–16.0)	9.9 (9.6–10.2)
Argentina	2057	13.9 (13.7–14.1)	15.2 (15.1–15.3)	13.5 (13.3–13.7)	14.8 (14.6–14.9)	50.1 (46.8–53.4)	36.5 (33.7–39.3)	12.2 (10.0–14.3)	11.9 (10.0–13.8)
Australia	2036	13.6 (13.4–13.8)	15.3 (15.2–15.5)	12.3 (12.1–12.6)	14.3 (14.2–14.5)	39.2 (35.7–42.7)	19.4 (17.3–21.6)	25.4 (22.3–28.4)	14.3 (12.4–16.2)
Belgium	2021	13.4 (13.2–13.6)	15.0 (14.9–15.1)	12.8 (12.5–13.0)	14.2 (14.1–14.4)	50.1 (46.5–53.8)	32.0 (29.4–34.5)	16.8 (14.1–19.5)	9.8 (8.1–11.4)
Brazil	2004	13.0 (12.8–13.1)	14.9 (14.7–15.0)	12.5 (12.3–12.8)	14.5 (14.3–14.7)	45.0 (41.7–48.3)	27.8 (25.2–30.4)	13.4 (11.1–15.6)	9.5 (7.8–11.2)
Canada	2029	13.3 (13.1–13.5)	15.3 (15.2–15.5)	12.3 (12.0–12.5)	14.5 (14.3–14.7)	39.8 (36.5–43.1)	17.2 (15.1–19.3)	15.1 (12.6–17.5)	6.4 (5.0–7.8)
China	2914	13.8 (13.7–14.0)	15.5 (15.4–15.6)	12.3 (12.1–12.5)	13.7 (13.6–13.8)	58.5 (55.4–61.5)	38.3 (36.2–40.5)	12.6 (10.5–14.6)	6.6 (5.5–7.8)
Colombia	2007	14.1 (14.0–14.3)	15.8 (15.6–15.9)	13.8 (13.6–14.0)	15.4 (15.2–15.6)	58.9 (55.5–62.2)	36.3 (33.5–39.1)	15.8 (13.4–18.3)	13.6 (11.6–15.6)
Egypt	2020	13.2 (13.1–13.4)	15.2 (15.0–15.3)	12.4 (12.2–12.6)	14.1 (14.0–14.3)	48.6 (45.4–51.8)	24.3 (21.7–26.9)	10.6 (8.6–12.5)	8.4 (6.7–10.1)
France	2019	13.4 (13.3–13.6)	14.9 (14.8–15.1)	12.7 (12.5–12.9)	14.3 (14.1–14.4)	44.8 (41.7–48.0)	28.5 (25.8–31.2)	14.0 (11.8–16.2)	8.9 (7.2–10.6)
Germany	2020	13.1 (12.9–13.3)	15.1 (14.9–15.2)	12.5 (12.3–12.8)	14.5 (14.3–14.7)	38.6 (35.1–42.1)	23.1 (20.8–25.4)	20.6 (17.7–23.5)	10.5 (8.8–12.1)
Holland	2008	13.4 (13.1–13.6)	15.8 (15.6–15.9)	12.7 (12.4–13.0)	14.7 (14.6–14.9)	45.5 (41.6–49.5)	20.2 (18.1–22.3)	10.7 (8.3–13.2)	4.1 (3.1–5.1)
Israel	2012	14.2 (14.0–14.3)	15.7 (15.6–15.8)	14.0 (13.8–14.3)	15.7 (15.6–15.9)	44.6 (41.0–48.2)	21.7 (19.4–23.9)	18.7 (15.9–21.5)	11.1 (9.4–12.8)
Italy	2063	13.8 (13.6–14.0)	15.2 (15.1–15.4)	12.4 (12.2–12.6)	13.9 (13.7–14.0)	52.8 (49.6–55.9)	34.3 (31.5–37.2)	21.1 (18.6–23.7)	18.8 (16.5–21.1)
Japan	2504	13.6 (13.5–13.8)	15.0 (14.9–15.1)	10.6 (10.4–10.8)	12.3 (12.1–12.4)	45.7 (42.6–48.8)	31.0 (28.7–33.4)	23.3 (20.7–25.9)	17.7 (15.7–19.6)
South Korea	2022	12.1(11.9–12.2)	13.5 (13.3–13.6)	10.7 (10.5–10.9)	12.3 (12.1–12.4)	50.3 (46.8–53.8)	30.6 (28.0–33.1)	19.7 (17.0–22.5)	15.6 (13.5–17.6)
Mexico	2001	13.6 (13.4–13.7)	15.3 (15.1–15.4)	13.5 (13.3–13.7)	15.1 (15.0–15.3)	72.1 (69.0–75.2)	48.9 (46.0–51.7)	21.6 (18.8–24.5)	19.2 (17.0–21.4)
Poland	2057	13.3 (13.2–13.5)	14.7 (14.6–14.8)	13.0 (12.8–13.2)	14.2 (14.0–14.3)	40.1 (37.0–43.3)	22.9 (20.4–25.4)	15.2 (12.9–17.5)	10.5 (8.6–12.3)
Romania	2049	13.4 (13.3–13.6)	14.9 (14.8–15.0)	13.4 (13.2–13.6)	14.7 (14.6–14.8)	37.5 (34.2–40.8)	24.4 (22.0–26.9)	15.7 (13.2–18.2)	10.7 (8.9–12.4)
Russia	2000	12.8 (12.6–12.9)	14.2 (14.1–14.4)	11.2 (11.0–11.4)	12.8 (12.6–13.0)	41.9 (38.7–45.2)	22.5 (20.0–24.9)	10.1 (8.1–12.1)	5.3 (4.0–6.6)
Singapore	2047	14.2 (14.0–14.4)	15.5 (15.4–15.6)	12.4 (12.2–12.7)	14.0 (13.8–14.1)	39.4 (35.6–43.2)	24.0 (21.8–26.3)	8.0 (5.9–10.1)	3.8 (2.8–4.8)
South Africa	2021	13.6 (13.5–13.8)	15.7 (15.5–15.8)	12.6 (12.4–12.8)	14.5 (14.3–14.7)	42.2 (39.0–45.4)	21.8 (19.4–24.3)	6.8 (5.2–8.4)	4.4 (3.2–5.6)
Spain	2072	13.8 (13.6–14.0)	15.4 (15.2–15.5)	13.2 (13.0–13.4)	14.6 (14.4–14.7)	59.6 (56.4–62.8)	38.3 (35.5–41.0)	16.4 (14.0–18.9)	8.7 (7.1–10.4)
Sweden	2084	13.4 (13.2–13.6)	15.0 (14.8–15.2)	12.3 (12.0–12.6)	14.6 (14.4–14.8)	35.8 (32.5–39.1)	19.7 (17.5–21.8)	5.7 (4.1–7.3)	2.9 (2.0–3.8)
Turkey	2010	13.1 (12.9–13.2)	14.4 (14.2–14.5)	12.1 (11.9–12.3)	13.5 (13.3–13.7)	42.5 (39.0–45.9)	21.7 (19.4–24.0)	20.2 (17.4–23.0)	13.0 (11.1–14.8)
USA	2023	13.6 (13.4–13.8)	15.8 (15.6–15.9)	13.1 (12.9–13.4)	15.3 (15.1–15.4)	35.9 (32.6–39.3)	16.0 (13.9–18.0)	19.7 (17.0–22.5)	8.9 (7.3–10.5)
UK	2027	13.1 (12.9–13.3)	15.5 (15.3–15.6)	12.0 (11.7–12.2)	14.4 (14.2–14.5)	42.7 (39.1–46.2)	18.8 (16.7–21.0)	14.8 (12.2–17.4)	4.8 (3.7–6.0)
<b>HOUSEHOLD</b>									
Pooled Estimates	<b>18949</b>	14.2 (14.1–14.3)	15.8 (15.8–15.9)	13.1 (13.0–13.2)	14.1 (14.1–14.2)	26.1 (24.8–27.4)	12.0 (11.5–12.4)	14.2 (13.1–15.2)	13.7 (13.1–14.2)
Bangladesh	2018	13.0 (12.8–13.2)	15.2 (15.1–15.3)	11.0 (10.8–11.1)	12.0 (11.9–12.1)	20.5 (17.8–23.3)	5.5 (4.3–6.8)	2.5 (1.4–3.5)	1.0 (0.4–1.6)
China	2710	14.8 (14.6–15.0)	16.7 (16.6–16.8)	13.1 (12.9–13.3)	14.4 (14.3–14.5)	37.5 (33.7–41.4)	15.9 (14.4–17.5)	16.1 (13.2–19.0)	6.5 (5.5–7.6)
Ghana	1190	16.4 (16.3–16.6)	17.4 (17.3–17.6)	17.3 (17.2–17.5)	17.7 (17.5–17.9)	2.7 (1.3–4.1)	9.9 (7.5–12.3)	13.6 (10.7–16.5)	24.3 (21.0–27.6)
India	4592	13.3 (13.0–13.6)	15.2 (15.1–15.3)	11.5 (11.3–11.8)	13.2 (13.1–13.3)	15.8 (11.8–19.7)	6.7 (5.9–7.5)	36.9 (31.6–42.1)	18.3 (17.1–19.5)
Indonesia	1231	15.4 (15.1–15.7)	16.7 (16.5–16.8)	13.6 (13.2–13.9)	14.3 (14.1–14.4)	18.8 (13.8–23.8)	6.0 (4.6–7.5)	23.1 (17.6–28.5)	9.3 (7.5–11.1)
Iran	1840	13.1 (12.9–13.4)	14.8 (14.6–14.9)	12.0 (11.8–12.3)	13.1 (12.9–13.2)	53.6 (49.2–58.0)	47.0 (44.3–49.7)	9.4 (6.8–11.9)	7.4 (6.0–8.8)
Malaysia	1976	14.9 (14.6–15.1)	16.3 (16.2–16.5)	14.1 (13.8–14.4)	15.2 (15.0–15.3)	30.4 (25.8–35.0)	7.3 (6.1–8.6)	14.9 (11.3–18.4)	15.1 (13.3–16.8)
Nigeria	1442	13.8 (13.5–14.1)	15.6 (15.5–15.8)	13.1 (12.9–13.4)	14.5 (14.4–14.7)	22.6 (18.2–27.0)	11.0 (9.1–12.8)	14.1 (10.5–17.7)	8.1 (6.4–9.7)
Turkey	1950	13.9 (13.5–14.3)	16.1 (16.0–16.2)	13.3 (12.8–13.8)	15.9 (15.7–16.0)	30.9 (23.4–38.4)	6.6 (5.5–7.8)	22.1 (15.4–28.9)	24.9 (22.9–26.9)

consulters, with one or more doctor visits per month for any health problem [(OR=1.7 (1.6–1.8)], but this difference was not seen in the household surveys [(OR=1.0 (0.9–1.2)] (Table 4). Also, individuals who met Rome IV criteria for any FGID were more likely to have visited doctors at any time in the past because of bowel problems than those with no FGID: 46.5% vs 27.1% in the Internet, and 26.1% vs 12.0% in the household survey. The same applied for each of the 5 selected major FGIDs.

Health-related QOL was lower on the PROMIS Global-10 questionnaire for individuals with any FGID compared with subjects with no FGID for global mental and global physical scores, in both Internet and household surveys. Most participants reported QOL scores in the middle of the possible range of scores, with little variability.

## Discussion

This is the first global study of the epidemiology and impact of the FGIDs (DGBIs). By assessing large population samples from 33 globally distributed countries using the same survey instruments and statistical analyses, we can provide a meaningful picture of FGIDs around the world. The study methodology was rigorous, especially for the 26 countries surveyed via the Internet, where we not only achieved predetermined parameters for sample size, sex, and age distribution, but also a national distribution that reflected closely the actual geographical population distributions.

Several findings are noteworthy from the results presented previously: (1) the overall rate for meeting at least 1 FGID diagnosis was generally consistent between countries within each sampling method, with a pooled mean of 40.3 (39.9–40.7) in Internet and 20.7 (20.2–21.3) in household countries. The rate of having any FGID was exceptionally low in the household surveys in Turkey and India, at less than 10%. (2) The prevalence of having any FGID was higher among women than men, with an OR of 1.7 (1.6–1.7) in Internet and 1.3 (1.3–1.4) in household countries. When surveyed via the Internet, 46.5% of the entire adult female population across the 6 continents surveyed met the diagnostic criteria for 1 or more of the FGIDs, supporting previous findings that FGIDs are more prevalent in women than in men. The corresponding figure for the household surveys was 23.1%. Our data show that the female predominance of FGIDs is present for FGIDs in all regions of the GI tract, from the esophagus to the rectum, and with both Internet and household survey methodologies. (3) IBS prevalence rates by Rome IV were lower than in most studies using previous versions of the Rome criteria<sup>9</sup> and generally half or less of Rome III prevalence rates in the same countries. This is in line with a recently published study in the United States, Canada, and the United Kingdom, that used a similar study methodology.<sup>21</sup> (4) Rome IV IBS rates were similar among most of the Internet countries, with 19 of the 26 having prevalence rates between 3% and 5%. Singapore and Egypt were clear outliers at 1.3% and 7.6%, respectively. In the household countries, the prevalence was more variable, ranging from 0.2% in India to 4.6% in Bangladesh. As has

been reported previously, we found women to have higher rates of IBS than men. We also found the sexes to have a different IBS subtype pattern: among women the rate of IBS-C is higher than IBS-D, whereas among men this is reversed. (5) In the Internet countries, FGID prevalence decreased with age, but there was an opposite trend seen in the household countries. (6) FGID prevalence rates for the household countries were consistently lower than the Internet countries. This also holds true for Turkey, even though their household survey methodology was much more similar to Internet surveys than in other household survey countries. Notably, the pattern of relative prevalence among the various disorders was consistent among the various FGIDs among all countries. (7) A few disorders, such as functional dysphagia, rumination, and proctalgia fugax, have prevalence rates that are higher than might be expected in light of clinical experience. It is possible that as we deepen our analyses of the entire database, some patterns may evolve that we are unaware of at the present.

Our findings on the cumulative presence of FGIDs (meeting diagnostic criteria for at least 1 FGID) are congruent with a previous study of the US population with the original Rome criteria (when there were 20 FGIDs) published in 1993,<sup>22</sup> which found 69% of US adults to have any FGID. The high prevalence in both cases is simply the result of evaluating simultaneously the presence of many disorders in the same population samples, yielding a comprehensive picture of the vast scope of FGIDs as a societal health problem.

Among the Internet-surveyed countries, the prevalence rates for many of the FGIDs, and IBS in particular, were quite similar and the variance was low. This illustrates that IBS and the other FGIDs are truly worldwide disorders. It also shows that the Rome IV diagnostic questionnaire can identify these disorders across geographic regions and in numerous translations. Yet, as has been reported previously,<sup>8,10,23</sup> there is variance among the countries in the prevalence of these disorders. There are several potential explanations for this variability, including cultural differences, social reporting sensitivity, ethnic diversity, genetics, and dietary habits. We are confident that the differences found in this study are not due to differences in study methodology, which was uniform within Internet and household surveys. Thus, in light of the rigorous and uniform research methodology we applied, we believe that the observed prevalence rates do accurately reflect differences among countries and are variable enough to warrant further investigation into reasons for differences between countries and regions,<sup>24,25</sup> and their association with potential predictive factors covered in our supplemental questionnaire. Such analyses can provide insights into more subtle aspects of the FGIDs and generate hypotheses for future research but are beyond the scope of the present article.

One of the more notable findings of our study is that IBS was less than half as prevalent using Rome IV compared with Rome III. This comparison was included in the study to assess whether worldwide regional prevalence differed according to the criteria used.<sup>26</sup> The current Rome IV criteria are more stringent, requiring at least *weekly* abdominal pain

(discomfort was not included), whereas Rome III required abdominal pain or discomfort at least 2 to 3 times monthly.<sup>27,28</sup> We believe that this change in criteria resulted, as previously reported,<sup>29–32</sup> in a shift in prevalence from IBS-C to FC and from IBS with diarrhea (IBS-D) to functional diarrhea, because the increased pain frequency threshold required for IBS was not reached or the subjects suffered from discomfort rather than pain. This is consistent with the approach of viewing individual patients with constipation on a pain frequency spectrum<sup>33</sup> where differences in pain occurrence determine shifts from IBS to FC or functional diarrhea.

The Rome IV IBS criteria, being more restrictive than Rome III, lead to more similar diagnostic groups for clinical research and drug trials. Consequently, the Rome IV criteria are identifying more severe cases of IBS, as also reflected in the IBS-SSS scores, rather than the totality of the condition as seen by clinicians. However, clinicians may not use such stringent criteria in practice, as treatment is likely to be the same even for “sub-threshold” patients with slightly less frequent abdominal pain. Clinicians tend to rely more on symptom presentation and clusters. Thus, the relative prevalence “shift” away from IBS may have more implications for recruitment into research studies, especially clinical trials, where the Rome IV criteria define a more severe or specific population than those seen in clinical practice. Because FC and functional diarrhea and their corresponding IBS subtypes often respond to the same therapies,<sup>34</sup> the shift in diagnosis may have less impact on treatment.

Unspecified functional bowel disorder was the most prevalent bowel diagnosis in our study. As it is the default diagnosis for people who have significant bowel symptoms but fail to qualify for another bowel disorder, the diagnostic criteria for functional bowel disorders, especially IBS, may be too restrictive. In contrast, the least prevalent subtype of IBS (Table 1) was IBS-U, so the addition of the Bristol Stool Form Scale as a discriminator for IBS subtypes may have facilitated the classification of the 3 specific subtypes (IBS-C, IBS-D, and IBS-M), reducing the number of nonspecific cases. Diagnostic criteria for cannabinoid hyperemesis syndrome, central abdominal pain syndrome, and functional biliary pain, where hardly any cases were identified, may also be restrictive. These disorders may be particularly difficult to identify in studies based on questionnaires. Previous studies have shown somewhat higher prevalence rates, especially for chronic abdominal pain syndrome, the more studied of these relatively rare disorders.<sup>22,35</sup>

Although the prevalence rates for many of the individual FGIDs were low, a large proportion of individuals met diagnostic criteria for at least 1 FGID. Combined with the findings that individuals meeting FGID criteria were twice as likely to consult doctors for bowel problems and had significantly lower general QOL than others, the collective burden of these disorders is substantial. The results of our study confirm that FGIDs are more prevalent among women than men. This is consistent with previous reports over the years.<sup>36</sup> Also consistent with previous reports, we found in the Internet surveys that FGIDs decreased with age.<sup>9</sup> However, in the household surveys, prevalence rates

tended to rise with increasing age, as discussed further as follows.

A key strength of this study that has implications for future research was the effectiveness of Internet surveys. Not only is this now becoming the default option in most countries because telephone and mail surveys are not feasible ways to reach the general population, but it provided reliable, quality-controlled data with a nationally representative distribution. This could not be accomplished with household surveys.

The most important limitations of our study relate to the lack of national representation and missing data in the household surveys (excepting Turkey). Furthermore, the necessity of relying on 2 different survey methodologies precluded calculation of pooled global prevalence rates for all 33 countries together.

The anonymous Internet survey methodology constitutes a very different survey experience for subjects than the face-to-face household survey methodology, and cultural sensitivities around reporting of FGID symptoms may have led to the large differences in prevalence rates observed between the 2 survey methods. Our assessment is that the Internet surveys provided more reliable estimates of prevalence rates because (1) we achieved national representation, and (2) we achieved more complete, accurate and reliable data collection because no question that required an answer could be skipped, and questions that should have been skipped, based on responses to key trigger questions, were always skipped and could not be answered. In addition, quality control measures including maximum speed of questionnaire completion, repeat questions for response consistency assessment, and attention-check questions were included. Finally, data were automatically and accurately entered into the study database, eliminating manual entry errors. Another strength of the study was the uniform translation methodology with linguistic validation and cultural adaptation, which also generated a repository of translated study questionnaires for future global research in FGIDs.

The pattern of relative prevalence among the various FGIDs was consistent in spite of the substantial differences in the absolute prevalence rates between the Internet and household surveys. Although the reasons for the lower mean FGID prevalence in the household surveys compared with the Internet surveys are unclear, there are several possible explanations. It could be a consequence of reluctance to report sensitive or intimate digestive tract symptoms in face-to-face interviews. This could be more salient in younger respondents, consistent with the unique finding in household countries that rates increased with age. Moreover, because we included only 1 subject per household and FGIDs often cluster in families, this method might have underestimated the prevalence.

There was a much higher percentage of household than Internet survey participants living in rural communities (43.3% vs 9.7%, respectively). We explored if this disparity could explain the difference in prevalence rates between the two survey types. We found that FGIDs were reported slightly more frequently in rural than urban areas in household survey countries OR 1.1 (1.0–1.2), while slightly

less frequently in rural than urban areas in Internet survey countries OR 0.9 (0.8–0.9), so this factor does not explain the difference, even in part. Because the prevalence rates were particularly low in India and Turkey (household), we rechecked the data entry process and the diagnostic scoring syntax, but no mistakes were found to explain this. The 2 geographically and linguistically separate sites surveyed in India had similarly low prevalence rates. To date, we have no definitive explanation for these unusually low rates, especially in light of the very different results from Bangladesh, a country with much in common with India.

Another limitation of the study is the lack of response rates for the Internet surveys and limited response rate information for the household surveys. However, in those countries for which we have precise data, Bangladesh, Malaysia, both regions in India, and Iran, the response rates were all more than 90%. Because similar participation encouragement methods were used in all household countries, we feel confident that the response rates were high in the others as well, although we do not have the exact figures.

An additional limitation of our study is that because it was a nonclinical questionnaire study of the general population, participants were not evaluated with procedures such as endoscopy or manometry, so some of the participants could have had an “organic” cause of their digestive symptoms. However, we believe that our inclusion of a checklist of organic diagnoses that might account for GI symptoms, and our exclusion of such cases from FGID prevalence counts (7.6% in Internet countries and 4.0% in household countries) compensated at least partially for this. A further limitation was that we attained less than satisfactory coverage of Africa and the Middle East. Our attempts to rectify this proved futile due to difficulties in recruiting interested investigators in the relevant countries.

The data collected with the supplemental questionnaire used in this study may yield findings on a range of variables with possible associations with FGIDs. Future analyses using those data will enable us to look at the relevance of differences in factors such as diet, hygiene, economic status, level of education, previous GI infections, and psychological comorbidity, with regard to FGID prevalence. These are likely to generate observations and hypotheses for further work that eventually may produce new insights into the pathophysiological mechanisms of FGIDs.

In conclusion, this article represents the first report documenting the global prevalence of FGIDs assessed with a uniform diagnostic questionnaire and research methodology. The results may influence substantially future planning of health care resources and clinical trials. Funding for research in the FGIDs is universally low, and they are viewed as a nonpriority. The data highlight a strong need and rationale for this to change. They should be of interest to multiple medical disciplines in addition to gastroenterologists, including general practitioners, family physicians, internists, nurses, dietitians, epidemiologists, public health experts, as well as other allied health care providers. We expect that the results presented here, and those to be reported from our future analyses, will serve as essential reference data for years to come.

## Supplementary Material

Note: To access the supplementary material accompanying this article, visit the online version of *Gastroenterology* at [www.gastrojournal.org](http://www.gastrojournal.org), and at <https://doi.org/10.1053/j.gastro.2020.04.014>.

## References

1. Drossman DA. Functional gastrointestinal disorder and the Rome IV process. In: Drossman DA, Chang L, Chey WD, et al, eds. *Functional gastrointestinal disorders. disorders of brain-gut interaction*. Volume 1. 4th ed. Raleigh, NC: Rome Foundation, 2016:1–32.
2. Sandler RS, Everhart JE, Donowitz M, et al. The burden of selected digestive diseases in the United States. *Gastroenterology* 2002;122:1500–1511.
3. Canavan C, West J, Card T. Review article: the economic impact of the irritable bowel syndrome. *Aliment Pharmacol Ther* 2018;40:1023–1034.
4. Tack J, Stanghellini V, Mearin F, et al. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. *BMC Gastroenterol* 2019;19:69.
5. Wong RK, Drossman DA. Quality of life measures in irritable bowel syndrome. *Expert Rev Gastroenterol Hepatol* 2010;4:277–284.
6. Higgins JP, Thompson SG. Controlling the risk of spurious findings from meta-regression. *Stat Med* 2004;23:1663–1682.
7. Quigley EM, Abdel-Hamid H, Barbara G, et al. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. *J Clin Gastroenterol* 2012;46:356–366.
8. Sperber AD, Dumitrascu D, Fukudo S, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: a Rome Foundation working team literature review. *Gut* 2016;66:1065–1072.
9. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. *Clin Gastroenterol Hepatol* 2012;10:712–721.
10. Ford AC, Marwaha A, Sood R, et al. Global prevalence of, and risk factors for, uninvestigated dyspepsia: a meta-analysis. *Gut* 2015;64:1049–1057.
11. El-Serag HB, Talley NJ. Systemic review: the prevalence and clinical course of functional dyspepsia. *Aliment Pharmacol Ther* 2004;19:643–654.
12. Palsson OS, Whitehead WE, van Tilburg MAL, et al. Development and validation of the Rome IV diagnostic questionnaire for adults. *Gastroenterology* 2016;150:1481–1491.
13. Kroenke K, Spitzer RL, Williams JB. The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms. *Psychosom Med* 2002;64:258–266.
14. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. *Aliment Pharmacol Ther* 1997;11:395–402.

15. Kroenke K, Spitzer RL, Williams JB, et al. An ultra-brief screening scale for anxiety and depression: the PHQ-4. *Psychosomatics* 2009;50:613–621.
16. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. In: Drossman SA, Corazziari E, Delvaux M, et al, eds. *Rome III. The functional gastrointestinal disorders*. McLean, VA: Degnon Associates, Inc.; 2006:487–555.
17. PROMIS Global-10. Available at: <https://www.codetechnology.com/promis-global-10/>.
18. Crane AL, Popielnicki A, Sperber AD, et al. Translatability evaluation of the Rome IV diagnostic questionnaire for adults. *Value in Health* 2016;19:A389.
19. Yang B. Meta prevalence estimates. Generating combined prevalence estimates from separate population surveys. NSW Department of Health, Center for Epidemiology and Research, 2007.
20. Defining Rural at the U.S. Census Bureau: American Community Survey and Geography Brief. Available at: [https://www2.census.gov/geo/pdfs/reference/ua/Defining\\_Rural.pdf](https://www2.census.gov/geo/pdfs/reference/ua/Defining_Rural.pdf).
21. Palsson OS, Whitehead W, Tornblom H, et al. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. *Gastroenterology* 2020;158:1262–1273.e3.
22. Drossman DA, Li Z, Andruzzi E, et al. U.S. householder survey of functional GI disorders: prevalence, socio-demography and health impact. *Dig Dis Sci* 1993;38:1569–1580.
23. Hungin AP, Whorwell PJ, Tack J, et al. The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects. *Aliment Pharmacol Ther* 2003;17:643–650.
24. Enck P, Aziz Q, Barbara G, et al. Irritable bowel syndrome. *Nat Rev Dis Primers* 2016;2:16014.
25. Fukudo S, Hahm KB, Zhu Q, et al. Survey of clinical practice for irritable bowel syndrome in East Asian countries. *Digestion* 2015;91:99–109.
26. Aziz I, Tornblom H, Palsson OS, et al. How the change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. *Am J Gastroenterol* 2018;113:1017–1025.
27. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. *Gastroenterology* 2006;130:1480–1491.
28. Lacy BE, Mearin F, Chang L, et al. Bowel disorders. *Gastroenterology* 2016;150:1393–1407.e5.
29. Lopez-Colombo A, Morgan D, Bravo-Gonzalez D, et al. The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study. *Gastroenterol Res Pract* 2012;2012:606174.
30. Schmulson M, Lopez-Colombo A, Mendoza-Gomez A, et al. The Rome III Adult Questionnaire in Spanish-Mexico has a low sensitivity for identifying IBS and higher sensitivity for uninvestigated dyspepsia. *Gastroenterology* 2012;143(Suppl. 1):S-829.
31. Sperber AD, Shvartzman P, Friger M, et al. A comparative reappraisal of the Rome II and Rome III diagnostic criteria: are we getting closer to the 'true' prevalence of irritable bowel syndrome? *Eur J Gastroenterol Hepatol* 2007;19:441–447.
32. Black CJ, Yiannakou Y, Houghton LA, et al. Epidemiological, clinical, and psychological characteristics of individuals with self-reported irritable bowel syndrome based on the Rome IV vs Rome III criteria. *Clin Gastroenterol Hepatol* 2020;18:392–398.e2.
33. Simren M, Palsson OS, Whitehead WE. Update on Rome IV criteria for colorectal disorders: implications for clinical practice. *Curr Gastroenterol Rep* 2017;19:15.
34. Simren M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. *Nat Rev Gastroenterol Hepatol* 2018;15:589–605.
35. Thompson WG, Irvine EJ, Pare P, et al. Functional gastrointestinal disorders in Canada: first population-based survey using Rome II criteria with suggestions for improving the questionnaire. *Dig Dis Sci* 2002;47:225–235.
36. Kim YS, Kim NY. Sex-gender differences in irritable bowel syndrome. *J Neurogastroenterol Motil* 2018;24:544–558.

Received February 15, 2020. Accepted April 1, 2020.

#### Correspondence

Address correspondence to: Ami D. Sperber, MD, MSPH, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel. e-mail: amiroie@me.com.

#### Acknowledgments

The authors thank Mr Jerry Schoendorf for his contribution to the graphic design of Fig. 1.

#### CRedit Authorship Contributions

Ami D. Sperber, MD, MSPH (Conceptualization: Lead; Data curation: Equal; Formal analysis: Supporting; Funding acquisition: Equal; Investigation: Lead; Methodology: Equal; Project administration: Lead; Resources: Equal; Supervision: Lead; Validation: Equal; Writing – original draft: Lead; Writing – review & editing: Lead). Shrikant I. Bangdiwala, PhD (Data curation: Equal; Formal analysis: Lead; Methodology: Lead; Supervision: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Douglas A. Drossman, MD (Conceptualization: Equal; Funding acquisition: Lead; Investigation: Equal; Methodology: Equal; Resources: Lead; Validation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Uday C. Ghoshal, MD, PhD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Supervision: Supporting; Validation: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Magnus Simren, MD, PhD (Conceptualization: Equal; Data curation: Equal; Investigation: Supporting; Methodology: Supporting; Resources: Equal; Validation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Jan Tack, MD, PhD (Conceptualization: Equal; Data curation: Equal; Investigation: Equal; Methodology: Supporting; Project administration: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). William E. Whitehead, PhD (Conceptualization: Supporting; Data curation: Supporting; Formal analysis: Supporting; Investigation: Equal; Methodology: Equal; Validation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Dan L. Dumitrascu, MD, PhD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Supporting). Xuicai Fang, MD, PhD (Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Supervision: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Shin Fukudo, MD, PhD (Data curation: Equal; Investigation: Supporting; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). John Kellow, MD (Data curation: Equal; Methodology: Supporting; Project administration: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Edith Okeke, MD (Data curation: Equal; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Eamonn Quigley, MD (Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Max Schmulson, MD (Conceptualization: Equal; Data curation: Equal; Investigation: Equal;

Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Peter Whorwell, MD (Conceptualization: Supporting; Data curation: Equal; Investigation: Supporting; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Timothy Archampong, MD (Data curation: Equal; Resources: Equal; Writing – original

draft: Equal; Writing – review & editing: Supporting). Payman Adibi, MD (Data curation: Equal; Methodology: Equal; Resources: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Viola Andresen, MD (Data curation: Equal; Investigation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Marc Benninga, MD (Data curation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Bruno Bonaz, MD (Data curation: Equal; Methodology: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Serhat Bor, MD (Data curation: Equal; Methodology: Equal; Resources: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Luis Bustos Fernández, MD (Data curation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Suck Chei Choi, MD (Data curation: Equal; Methodology: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Enrico Stefano Corazziari, MD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Carlos Francisconi, MD (Data curation: Equal; Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Albi Hani, MD (Data curation: Equal; Investigation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Leonid Lazebnik, MD (Data curation: Equal; Methodology: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Yeong Lee, MD (Data curation: Equal; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Agata Mulak, MD (Data curation: Equal; Investigation: Supporting; Methodology:

Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). M. Masudur Rahman, MD (Data curation: Equal; Investigation: Supporting; Methodology: Supporting; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Javier Santos, MD (Data curation: Equal; Methodology: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Mashiko Setshedi, ND (Data curation: Equal; Investigation: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Ari Farhrial Syam, MD (Data curation: Equal; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Stephen Vanner, MD (Data curation: Equal; Methodology: Supporting; Writing –

original draft: Equal; Writing – review & editing: Equal). Reuben Wong, MD (Data curation: Equal; Investigation: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Aurelio Lopez-Colombo, MD (Data curation: Equal; Writing – original draft: Equal;

Writing – review & editing: Equal). Valeria Atenea Costa, MD (Data curation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Ram Dickman, MD (Data curation: Equal; Methodology: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Motoyori Kanazawa, MD (Data curation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Ammar Hassanzadeh, MD (Data curation: Equal; Methodology: Equal; Project administration: Supporting; Writing – original draft: Equal; Writing – review & editing: Equal). Rutaba Khatun, MSc (Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Iradj Maleki, MD (Data curation: Equal; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Pierre Poitras, MD (Data curation: Equal; Methodology: Supporting; Writing – original

draft: Equal; Writing – review & editing: Equal). Nitesh Pratap, MS (Data curation: Equal; Methodology: Equal; Project administration: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Oksana Stefanyuk, MD (Data curation: Equal; Investigation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Sandie Thomson, MD (Data curation: Equal; Investigation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Judith Zeevenhooven, BSc (Data curation: Equal; Investigation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal). Olafur Palsson, PsyD (Conceptualization: Equal; Data curation: Equal; Formal analysis: Equal; Investigation: Equal; Methodology: Equal; Project administration: Equal; Software: Lead; Validation: Equal; Writing – original draft: Equal; Writing – review & editing: Equal).

#### Conflict of interest


The authors disclose no conflicts.

#### Funding

The study was funded, in part, by research grants from Ironwood, Shire, Allergan, and Takeda. The study in Malaysia was funded by the Fundamental Research Grant Scheme (FRGS) of the Ministry of Education of Malaysia (Reference: 203.PPSP.6171192). The study in Israel was funded by Takeda-Israel. The study in Romania was funded by the Romanian Society of Neurogastroenterology. None of the funders was involved in the planning, design, implementation, statistical analyses or any other aspect of the study including preparation of the paper or knowledge of its contents.



# IBS



**Supplementary Fig. 1.** Global maps showing study countries (Internet above, household below), color-coded for prevalence of IBS.

**Supplementary Table 1.** Item Content of the Entire Global Study Questionnaire

Question content	No. of questions
Demographic questions:	
Age	1
Sex	1
Years of education	1
Relationship status	1
Size of local community where respondent lives	1
Region (eg, state, province) of residence	1
Race/Ethnicity (not administered in all survey countries)	1
Religious/spiritual self-identification	1
Personal Health Questionnaire-15 (PHQ-15)	15
Rome IV Diagnostic Questionnaire for Adult FGIDs	89
IBS-SSS	7
Current living conditions: Whether respondent lives on a farm, has running water and electricity, daily access to telephone and internet, number of people in the household, number of bedrooms and toilets·	4
Childhood living conditions up to age 7: Whether respondent lived on a farm, had running water and electricity, number of people in the household, number of bedrooms and toilets·	4
Childhood country of residence	1
Childhood size of local community	1
Access to medical care if needed	1
Type of medical care that would be sought if needed (Western style medicine and/or traditional or folk healer	1
Frequency of doctor visits	1
Who pays for medical expenses	1
History of medical diagnoses (checklist of 12 GI diagnoses and conditions that may affect FGIDs)	1
History of GI and abdominal surgeries· Checklist of 5 surgery types	1
Medications taken regularly (at least once a week)· Yes/no list of 10 types of medications	1
Bowel infection history: Whether current bothersome symptoms first started immediately after bowel infection	1
Symptoms, conditions and treatment of bowel infection preceding first onset of current bothersome bowel symptoms	2
History of visiting doctor because of a bowel problem (yes/no)	1
Type of doctor seen for bowel problems	1
Concern about own bowel functioning (yes/no)	1
Embarrassment about bowel functioning (yes/no)	1
Impact of stress, pressure or tension on bowel functioning (yes/no)	1
Diet: Days per week of consumption of 10 food types	1
PROMIS Global-10 quality of life questionnaire	10
Personal Health Questionnaire – 4 (PHQ-4): Anxiety and depression screening measure	4
Height and weight	2
Rome III diagnostic questions for IBS (not administered in all countries)	8

**Supplementary Table 2.** Countries, Language, and Distribution by Sex and Age for the Internet and Household Surveys

Country	Languages	N	Sex distribution (%)		Age distribution (%)		
			Male (50%)	Female (50%)	18–39 (40%)	40–64 (40%)	65+ (20%)
Internet							
Argentina	Spanish (L)	2,058	50.6	49.4	39.5	40.2	20.4
Australia	English (L)	2,037	50.2	49.8	39.8	40.2	20.0
Belgium	French (L), Dutch (L)	2,021	50.1	49.9	40.2	40.0	19.8
Brazil	Portuguese (O)	2,000	50.0	50.0	39.8	40.0	20.2
Canada	English (L), French (L)	2,029	50.1	49.9	39.9	40.0	20.1
China	Chinese (O)	3,013	50.2	49.8	40.1	40.1	19.8
Colombia	Spanish (L)	2,088	49.9	50.1	41.1	43.4	15.4
France	French (O)	2,043	49.9	50.1	40.2	40.8	19.0
Germany	German (O)	2,042	49.8	50.2	40.3	40.2	19.5
Holland	Dutch (O)	2,008	50.0	50.0	39.8	40.1	20.1
Israel	Hebrew (O), Arabic (L), Russian (L), English (L)	2,014	50.0	50.0	40.3	40.4	19.3
Italy	Italian (O)	2,073	50.3	49.7	39.9	40.2	19.9
Japan	Japanese (O)	2,504	48.6	51.4	40.5	39.8	19.7
Mexico	Spanish (O)	2,001	50.4	49.6	40.4	40.4	19.2
Poland	Polish (O)	2,057	49.9	50.1	40.2	40.1	19.7
Romania	Romanian (O)	2,049	50.1	49.9	40.5	54.9	4.6
Russia	Russian (O)	2,000	50.7	49.3	40.0	40.3	19.7
Singapore	English (L), Chinese (L), Bahasa Malay (L)	2,047	50.0	50.0	47.7	48.6	3.7
South Africa	English (L)	2,023	50.3	49.7	53.1	40.6	6.3
South Korea	Korean (O)	2,085	50.4	49.6	38.6	51.0	10.3
Spain	Spanish (L)	2,071	50.2	49.8	39.8	40.3	19.9
Sweden	Swedish (O)	2,088	50.2	49.8	39.8	40.1	20.1
Turkey	Turkish (O)	2,010	49.8	50.2	50.1	44.7	5.2
United Kingdom	English (L)	2,027	50.1	49.9	39.8	40.1	20.1
United States	English (O)	2,026	50.1	49.9	39.8	40.0	20.2
Household							
Bangladesh	Bengali (L)	2018	49.01	50.99	39.69	40.39	19.92
China	Chinese (O)	2710	47.42	52.58	33.32	47.27	19.41
Ghana	English (L)	1190	51.09	48.91	40.92	40.34	18.74
India	Hindi (O), Telugu (O), Bengali (O)	4592	50.20	49.80	42.09	41.70	16.20
Indonesia	Bahasa (L)	1231	48.90	51.10	39.32	40.70	19.98
Iran	Farsi (O)	1840	49.84	50.16	40.16	40.00	19.84
Malaysia	Bahasa-Malay (O)	1976	47.67	52.33	46.51	40.13	13.36
Nigeria	English (L)	1442	51.53	48.47	39.67	41.68	18.65
Turkey	Turkish (O)	1950	50.67	49.33	53.69	43.49	2.82

NOTE. The planned sex distribution was 50/50 and the planned age distribution was 40% (18–39), 40% (40–64), and 20% (65+). L, localized translation; O, original translation.